These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 24692765)

  • 1. Effects of valsartan on inflammatory and oxidative stress markers in hypertensive, hyperglycemic patients: an open-label, prospective study.
    Kuboki K; Iso K; Murakami E; Abe S; Araki E; Ueshiba H; Yoshino G
    Curr Ther Res Clin Exp; 2007 Sep; 68(5):338-48. PubMed ID: 24692765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rosuvastatin on concentrations of plasma lipids, urine and plasma oxidative stress markers, and plasma high-sensitivity C-reactive protein in hypercholesterolemic patients with and without type 2 diabetes mellitus: A 12-week, open-label, pilot study.
    Yoshino G; Tanaka M; Nakano S; Matsumoto T; Kojima M; Murakami E; Morita T
    Curr Ther Res Clin Exp; 2009 Dec; 70(6):439-48. PubMed ID: 24692836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure.
    Sakamoto M; Suzuki H; Hayashi T; Iuchi H; Isaka T; Sakamoto N; Kayama Y; Tojo K; Yoshimura M; Utsunomiya K
    Cardiovasc Diabetol; 2012 Oct; 11():118. PubMed ID: 23034088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
    Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
    Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cardiovascular risk factors and inflammatory status on urinary 8-OHdG in essential hypertension.
    Roselló-Lletí E; de Burgos FG; Morillas P; Cortés R; Martínez-Dolz L; Almenar L; Grigorian L; Orosa P; Portolés M; Bertomeu V; Rivera M
    Am J Hypertens; 2012 Feb; 25(2):236-42. PubMed ID: 22052073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension.
    Komiya N; Hirose H; Saisho Y; Saito I; Itoh H
    Int Heart J; 2008 Nov; 49(6):681-9. PubMed ID: 19075484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
    Ogawa S; Mori T; Nako K; Kato T; Takeuchi K; Ito S
    Hypertension; 2006 Apr; 47(4):699-705. PubMed ID: 16505207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
    Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T
    Thromb Res; 2006; 117(4):385-92. PubMed ID: 15896827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care.
    Yajima K; Shimada A; Hirose H; Oikawa Y; Yamada S; Meguro S; Irie J; Irie S
    Clin Drug Investig; 2009; 29(12):811-9. PubMed ID: 19888787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets).
    Shishido T; Konta T; Nishiyama S; Miyashita T; Miyamoto T; Takasaki S; Nitobe J; Watanabe T; Takeishi Y; Kubota I
    Clin Exp Hypertens; 2011; 33(2):117-23. PubMed ID: 21269062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats.
    Cheng ZJ; Vaskonen T; Tikkanen I; Nurminen K; Ruskoaho H; Vapaatalo H; Muller D; Park JK; Luft FC; Mervaala EM
    Hypertension; 2001 Feb; 37(2 Pt 2):433-9. PubMed ID: 11230314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
    Ogawa S; Mori T; Nako K; Ito S
    Hypertens Res; 2008 Jun; 31(6):1147-55. PubMed ID: 18716362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between ceruloplasmin and oxidative biomarkers including ferritin among healthy Japanese.
    Inoue K; Sakano N; Ogino K; Sato Y; Wang DH; Kubo M; Takahashi H; Kanbara S; Miyatake N
    J Clin Biochem Nutr; 2013 Mar; 52(2):160-6. PubMed ID: 23524455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with an angiotensin-converting-enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy.
    Nakamura A; Shikata K; Nakatou T; Kitamura T; Kajitani N; Ogawa D; Makino H
    J Diabetes Investig; 2013 Mar; 4(2):195-201. PubMed ID: 24843652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress biomarkers and lifestyles in Japanese healthy people.
    Sakano N; Wang DH; Takahashi N; Wang B; Sauriasari R; Kanbara S; Sato Y; Takigawa T; Takaki J; Ogino K
    J Clin Biochem Nutr; 2009 Mar; 44(2):185-95. PubMed ID: 19308273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relation of oxidative DNA damage to hypertension and other cardiovascular risk factors in Tanzania.
    Negishi H; Ikeda K; Kuga S; Noguchi T; Kanda T; Njelekela M; Liu L; Miki T; Nara Y; Sato T; Mashalla Y; Mtabaji J; Yamori Y
    J Hypertens; 2001 Mar; 19(3 Pt 2):529-33. PubMed ID: 11327625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High oxidative stress is correlated with frailty in elderly chinese.
    Wu IC; Shiesh SC; Kuo PH; Lin XZ
    J Am Geriatr Soc; 2009 Sep; 57(9):1666-71. PubMed ID: 19682113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter Ozone Study in oldEr Subjects (MOSES): Part 1. Effects of Exposure to Low Concentrations of Ozone on Respiratory and Cardiovascular Outcomes.
    Frampton MW; Balmes JR; Bromberg PA; Stark P; Arjomandi M; Hazucha MJ; Rich DQ; Hollenbeck-Pringle D; Dagincourt N; Alexis N; Ganz P; Zareba W; Costantini MG
    Res Rep Health Eff Inst; 2017 Jun; 2017(192, Pt 1):1-107. PubMed ID: 31898880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.